Purified cannabidiol leads to improvement of severe treatment-resistant behavioral symptoms in children with autism spectrum disorder

IF 2.5 3区 心理学 Q1 BEHAVIORAL SCIENCES Pharmacology Biochemistry and Behavior Pub Date : 2025-04-01 Epub Date: 2025-02-16 DOI:10.1016/j.pbb.2025.173971
Pablo Sebastián Fortini , Javier J. Toibaro , Roberto H. Caraballo
{"title":"Purified cannabidiol leads to improvement of severe treatment-resistant behavioral symptoms in children with autism spectrum disorder","authors":"Pablo Sebastián Fortini ,&nbsp;Javier J. Toibaro ,&nbsp;Roberto H. Caraballo","doi":"10.1016/j.pbb.2025.173971","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The aim of our study was to evaluate the efficacy and safety of purified cannabidiol as an add-on medication in pediatric patients with autism spectrum disorder (ASD) associated with treatment resistant repetitive behaviors, behavior disorders, and intellectual disability and unresponsive to conventional medications and behavioral interventions.</div></div><div><h3>Material and methods</h3><div>A prospective, observational, before-and-after study was conducted including 20 patients with severe ASD who initiated treatment with purified CBD. Patients were evaluated using different scales at baseline and at three-month intervals during followup.</div></div><div><h3>Results</h3><div>The median total CBD dose was 363.5 mg (range, 100–700), and the median follow-up was 11 months (range, 6–12). As to the primary outcome evaluating symptoms reported by parents, improvement in at least one was observed after CBD initiation in 18 patients (90 %) and no improvement in two (10 %) (1 worsening, 1 no response). In the responders, 83.5 % (<em>n</em> = 76) of all reported symptoms improved. Regarding the secondary outcomes based on the assessment with different scales, improvement of around 30 % was found in irritability, social withdrawal, hyperactivity. Restricted and repetitive behavior improved in nine (50 %), while no changes were seen in seven (38.8 %). Sleep patterns were found to be slightly improved. Adverse effects were reported in 13 patients (65 %), mainly consisting of increased irritability and decreased appetite, but were mild or moderate and transient in all. In 40 % of the children, concomitant medication could be reduced or partially discontinued.</div></div><div><h3>Conclusion</h3><div>Our results suggest that treatment with purified CBD is effective and safe and could benefit patients with severe ASD by improving some of the core symptoms, including repetitive behaviors and social interaction, as well as associated comorbidities. The families considered the quality of life to have improved.</div></div>","PeriodicalId":19893,"journal":{"name":"Pharmacology Biochemistry and Behavior","volume":"249 ","pages":"Article 173971"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Biochemistry and Behavior","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091305725000188","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The aim of our study was to evaluate the efficacy and safety of purified cannabidiol as an add-on medication in pediatric patients with autism spectrum disorder (ASD) associated with treatment resistant repetitive behaviors, behavior disorders, and intellectual disability and unresponsive to conventional medications and behavioral interventions.

Material and methods

A prospective, observational, before-and-after study was conducted including 20 patients with severe ASD who initiated treatment with purified CBD. Patients were evaluated using different scales at baseline and at three-month intervals during followup.

Results

The median total CBD dose was 363.5 mg (range, 100–700), and the median follow-up was 11 months (range, 6–12). As to the primary outcome evaluating symptoms reported by parents, improvement in at least one was observed after CBD initiation in 18 patients (90 %) and no improvement in two (10 %) (1 worsening, 1 no response). In the responders, 83.5 % (n = 76) of all reported symptoms improved. Regarding the secondary outcomes based on the assessment with different scales, improvement of around 30 % was found in irritability, social withdrawal, hyperactivity. Restricted and repetitive behavior improved in nine (50 %), while no changes were seen in seven (38.8 %). Sleep patterns were found to be slightly improved. Adverse effects were reported in 13 patients (65 %), mainly consisting of increased irritability and decreased appetite, but were mild or moderate and transient in all. In 40 % of the children, concomitant medication could be reduced or partially discontinued.

Conclusion

Our results suggest that treatment with purified CBD is effective and safe and could benefit patients with severe ASD by improving some of the core symptoms, including repetitive behaviors and social interaction, as well as associated comorbidities. The families considered the quality of life to have improved.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纯化大麻二酚可改善自闭症谱系障碍儿童的严重治疗抵抗行为症状
目的:本研究旨在评估纯化大麻二酚作为附加药物治疗自闭症谱系障碍(ASD)儿童患者的有效性和安全性,ASD患者伴有治疗抵抗性重复行为、行为障碍和智力残疾,对常规药物和行为干预无反应。材料与方法进行了一项前瞻性、观察性、前后对照研究,包括20例开始使用纯化CBD治疗的严重ASD患者。在基线和随访期间每隔3个月使用不同的量表对患者进行评估。结果中位总CBD剂量为363.5 mg(范围100-700),中位随访时间为11个月(范围6-12)。至于评估家长报告的症状的主要结局,18例患者(90%)在开始使用CBD后至少有1例患者(90%)得到改善,2例(10%)没有改善(1例恶化,1例无反应)。在应答者中,83.5% (n = 76)的所有报告症状得到改善。根据不同量表评估的次要结果,在易怒、社交退缩、多动方面改善约30%。限制性和重复性行为在9例(50%)中有所改善,而在7例(38.8%)中没有变化。睡眠模式也略有改善。13例(65%)患者报告了不良反应,主要包括易怒增加和食欲下降,但均为轻度或中度和短暂性。在40%的儿童中,可减少或部分停用伴随用药。我们的研究结果表明,纯化CBD治疗是有效和安全的,可以通过改善一些核心症状,包括重复行为和社交互动,以及相关的合并症,使严重ASD患者受益。这些家庭认为生活质量提高了。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.40
自引率
2.80%
发文量
122
审稿时长
38 days
期刊介绍: Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided.
期刊最新文献
Acute chlordiazepoxide increases risky choice in rats and repeated administration attenuates this effect Agmatine diminishes pro-inflammatory response by modulating IL-1β and NF-κB expression in the prefrontal cortex and reverses behavioral impairments following chronic social isolation in rats Parental care shapes anxiety-like behavior, oxytocin, social interaction, and ethanol sensitivity in adolescent C57BL/6J mice Dexmedetomidine pre-injection attenuates fear response via prelimbic cortex modulation in an electric shock–induced PTSD adolescent rat model Loneliness, serotonin, and medial prefrontal cortex: some empirical and theoretical considerations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1